Santhera finds Chinese marketing partner for vamorolone
Swiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1254 entries already.
Swiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone.
Moderna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.
Novo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put 110m in the first fund of Sound Bioventures AB.
The new year begins with good news.
Merry Christmas and a Happy New Year!
Novo Holdings is set to invest 86m in 21st.BIO A/S a new Danish bioindustrial scale-up company to boost the production of proteins.
Ocular gene therapy specialist Gyroscope Therapeutics Holdings plc is to be acquired by Novartis AG for up to $1.5bn.
Dutch metabolic disease specialist NorthSea Therapeutics NV has baged US$80m in a Series C fundraising co-led by Ysios Capital and Forbion Growth.
French-British magnetic trap specialist Depixus has raised 30,6m to develop a commercial instrument based on the companys MAGNA technology.
Ichnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders.